



## Supplementary Figure S4




**Supplementary Figure S4. Bone marrow cellularity and immune cells are not reduced by everolimus.** Four week old wild-type mice (WT) and  $E\mu$ -Myc transgenic (TG) mice were treated with placebo (P) or everolimus (E). **(A)** Bone marrow cellularity. **(B-E)** The percentage granulocytes (Ly6G<sup>-</sup>/CD11b<sup>hi</sup>/F4-80<sup>int</sup>), macrophages (Ly6G<sup>-</sup>/CD11b<sup>hi</sup>/F4-80<sup>hi</sup>), T-cells (NK1.1<sup>-</sup>/abTCR<sup>+</sup>) and NK cells (NK1.1<sup>+</sup>/abTCR<sup>-</sup>) were determined by flow cytometry.

## Supplementary Figure S5

**A**




**B**




**Supplementary Figure S5. Heightened sensitivity of B-cells expressing oncogenic levels of MYC to mTORC1 inhibition by everolimus.** Four week old wild-type mice (WT) and E $\mu$ -Myc transgenic (TG) mice were treated with placebo (P) or everolimus (E). The number of B220+/CD19+ B cells in the bone marrow (**A**) and spleen (**B**) were analyzed on day 4. p values were generated using a Student's unpaired 2-tailed t-test. NS=not significant. \*=p<0.05.

## Supplementary Figure S6

**A**



**B**



**Supplementary Figure S6. Survival benefit of everolimus in  $E\mu$ -Myc lymphomas.** Survival curves for syngeneic mice injected with  $E\mu$ -Myc lymphoma cells and treated with everolimus or placebo. **(A)** Tumor #4242,  $n=10$  mice per group. Median survival was 14 days for placebo and 19.5 days for everolimus ( $p=0.001$ ). **(B)** Tumor #107,  $n=5$  mice per group. Median survival was 11 days for placebo and 16 days for everolimus ( $p<0.001$ ).